New Investment Targets Obesity-Linked Cancer Risk
A new venture-backed firm aims to study if GLP-1 medications can lower the risk of 14 specific cancer types.
Updated on Oct. 28, 2026 in Cancer
Live Poll
Do you believe GLP-1 medications are the most promising solution for improving long-term health outcomes?
Reed Jobs' oncology-focused venture firm Yosemite recently exceeded its $350 million fundraising target. This investment push arrives as researchers investigate how emerging medications like GLP-1s might help lower cancer risk by addressing obesity, a primary health factor.
Why it matters
With the American Cancer Society projecting 2.1 million new U.S. cancer diagnoses in 2026, finding new ways to reduce risk factors is critical. Obesity is currently associated with 40% of all cancers diagnosed annually in the U.S.
A JAMA Oncology study following 86,632 adults found a 17% lower hazard of developing 14 obesity-related cancers among GLP-1 users. This cohort research highlights a potential preventive benefit, though further investigation is needed to confirm direct causation.
The players
Reed Jobs
The founder of the oncology-focused venture capital firm Yosemite.
American Cancer Society
A national organization dedicated to cancer research, patient services, and prevention education.
Yosemite
A venture capital firm focused on investing in new oncology treatments and cancer research.
The details
GLP-1 medications may lower cancer risk primarily by helping patients manage excess body weight, which is linked to 7.6% of U.S. cancer cases. By regulating metabolism and reducing weight-related inflammation, these drugs could potentially shift how obesity-related cancer risk is managed. The firm aims to advance these types of clinical solutions to move toward managing cancer as a chronic condition rather than a fatal one.
Timeline
2003: Reed Jobs' father is diagnosed with pancreatic cancer.
2024: The American Cancer Society reports links between smoking, obesity, and cancer.
2025: JAMA Oncology publishes research on GLP-1 drugs and cancer risk.
2026: The U.S. faces a projection of 2.1 million cancer diagnoses.
Health Landscape
This development aligns with the American Cancer Society's cancer prevention research, which underscores that weight management is a major modifiable risk factor. It marks a shift toward leveraging metabolic drugs as a tool in the broader effort to reduce the national cancer burden.
Understanding the link between obesity and cancer risk is an important topic to discuss with your primary care physician during your next checkup. Your doctor can help determine if your personal health profile suggests weight management strategies might be beneficial for long-term prevention.
The takeaway
Obesity-related conditions represent a significant, modifiable risk factor for many common cancers. Maintaining a healthy weight and discussing screening schedules with your physician are actionable steps to support your long-term health.
Further reading
For more on the current research landscape, visit our Cancer section.
Source note: This article includes information reported by Fortune.
Live Poll
Do you believe GLP-1 medications are the most promising solution for improving long-term health outcomes?
